Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) and OncXerna Therapeutics, Inc., a precision medicine company, announced today they have entered an...
Ashleyr Robinson Matt Franklin Stephanie Spanos Laura Benjamin Megan Jones Precision Oncology For Exact Sciences
Source: prnewswire.com